Effects of Marine Phospholipids Extract on the Lipid Levels of Metastatic and Nonmetastatic Prostate Cancer Patients

Table 1

Baseline characteristics of the study population.

Study population
Patients		Subjects without PCa
Age (years)	68 (48–83)	Age (years)	74 (70–85)^a
median (min–max)		median (min–max)
BMI (kg/m^2)	26 (20.6–41.6)	BMI (kg/m^2)	26.3 (22.2–34)^b
median (min–max)		median (min–max)
PCa disease ()		Urological condition ()
Metastasized PCa	18	BPH	21
PCa	20	Kidney stones	2
PCa in remission	45	PCa biopsies with neg. result	2
Unknown PCa status	10	High grade PIN^h	2
		Other^i	4
Gleason score ()
≤7a	56
≥7b	58
Therapy ()^c		Therapy ()^j
Chemotherapy^d	6	Surgery^f	22
Radiotherapy^e	2	No therapy	9
Hormone therapy	15
Surgery^f	53
Active surveillance	7
No therapy^g	10

Age difference between both groups was statistically not significant ().
^bBMI difference between both groups was statistically not significant ().
^cReferred to the ongoing therapy at study enrolment.
^dDocetaxel, taxol, folfox, or taxotere.
^eIncluding brachytherapy.
^fTUR-P or RRP with or without lymphadenectomy.
^gNo therapy in the last 6 months.
^hHigh-grade prostatic intraepithelial neoplasia.
ⁱStrangury, renal hematoma, bladder neck stenosis, and hematuria.
^jTUR-P, transurethral incision of the prostate (TUIP), percutaneous nephrolithotomy, bladder neck incision, spermatocelectomy, open adenoma enucleation, transurethral laser vaporization, or placement of prostatic stent.